Clinical Study
The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial
Table 2
Safety endpoints at year 3.
| ||||||||||||||||||||||||||||||||
MACE, major adverse cardiovascular event; CNI, calcineurin inhibitor. |